| Lucksinger, Gregg |
NCT04318548 / 2016-003722-16: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age |
|
|
| Completed | 3 | 943 | Europe, US | Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Bexsero, Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Menveo, Placebo, NaCl, saline solution | GlaxoSmithKline | Infections, Meningococcal | 11/23 | 11/23 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05089630: A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults |
|
|
| Active, not recruiting | 1/2 | 333 | US | Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline) | GlaxoSmithKline | Cytomegalovirus Infections | 06/25 | 06/25 | | |
NCT05853380: A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients |
|
|
| Completed | N/A | 85 | US | Informed Vital Core App | Mindset Medical | Vital Sign Evaluation | 06/23 | 06/23 | | |
| Peterson, Daniel |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
| Available | N/A | | US | Poly I: Poly C12U (Rintatolimod), Ampligen, Rintatolimod | AIM ImmunoTech Inc. | Chronic Fatigue Syndrome | | | | |
| Recruiting | N/A | 300 | US | coflex® Interlaminar Technology, coflex, Decompression | Xtant Medical, MCRA | Spinal Stenosis Lumbar | 09/24 | 11/27 | | |
NCT05405374: OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study |
|
|
| Recruiting | N/A | 101 | US | OSTEOAMP, Infuse | Bioventus LLC | Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease | 10/24 | 10/25 | | |
| Jolly, Meenakshi |
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/25 | 03/26 | | |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE |
|
|
| Recruiting | N/A | 200 | US | Decision Support Test | Ampel BioSolutions, LLC | Lupus Erythematosus, Systemic | 12/24 | 03/25 | | |
| Pickrell, Paul |
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
| Completed | 3 | 4223 | Europe, US | ABNCoV2, Comirnaty | Bavarian Nordic | COVID-19 Disease | 03/23 | 10/23 | | |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) |
|
|
| Active, not recruiting | 3 | 292 | Europe, Japan, US, RoW | TILD, matching placebo injections | Sun Pharmaceutical Industries Limited | Active Psoriatic Arthritis | 09/24 | 12/24 | | |
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) |
|
|
| Recruiting | 3 | 472 | Europe, Canada, US, RoW | TILD, matching placebo injections | Sun Pharmaceutical Industries Limited | Active Psoriatic Arthritis | 05/25 | 02/26 | | |
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriatic Arthritis, Obesity | 04/26 | 08/26 | | |
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/25 | 03/26 | | |
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. |
|
|
| Completed | 2/3 | 660 | US | XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant | Novavax | COVID-19 | 11/23 | 05/24 | | |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Terminated | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 1380 | US | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |
NCT05975840: Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults |
|
|
| Completed | 1/2 | 518 | US | FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A, FLU Q-PAN H5N8 Formulation 2 | GlaxoSmithKline | Influenza, Human | 12/23 | 05/24 | | |
| Recruiting | N/A | 28 | Europe, US | Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment | Galvani Bioelectronics, NAMSA, Q2 Solutions | Rheumatoid Arthritis | 07/27 | 04/32 | | |
| Holleran, Jeffrey |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
| Ronholm, Chad M |
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/25 | 03/26 | | |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
| Korvana, Jessica |
| Completed | 3 | 4223 | Europe, US | ABNCoV2, Comirnaty | Bavarian Nordic | COVID-19 Disease | 03/23 | 10/23 | | |
| Pullman, Lyric |
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. |
|
|
| Completed | 2/3 | 660 | US | XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant | Novavax | COVID-19 | 11/23 | 05/24 | | |
| Okoli, Tiffany |
NCT06000410: A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
|
|
| Recruiting | 3 | 474 | US | Amniotic Suspension Allograft, Placebo | Organogenesis | Knee Osteoarthritis | 09/25 | 03/26 | | |
